MORE DD
Return to
Disease Category
Listing
Additional resources
in this illness area
Trial Information
Summary: A study on treatment for HIV.
An ongoing 48 week medical research study involving MKC-442, a new Non-Nucleoside Reverse Transcriptase
Inhibitor (NNRTI), in combination with Viracept, a Protease Inhibitor, and two Nucleoside Reverse Transcriptase
Inhibitors (NRTIs). The goal is to determine if MKC-442 plus Viracept results in a better reduction in HIV-1 RNA
compared with Viracept with either d4T+3TC or d4T+ddI. After initial screen and baseline visits, study visits are
conducted monthly for 6 months, then every 2 months until study completion. All study medication will be
provided free of charge while participating in the study and HIV-1 PCR results will be provided in real time.
Patient/Inclusion/Exclusion Criteria:
HIV infected with a recent plasma HIV-1 RNA 10,000 copies per ml or greater
Currently receiving dual treatment with two NRTIs (AZT, 3TC, ddI and/or d4T) for greater than 16 weeks
Willing and able to switch NRTI therapy to either d4T+3TC or d4T+ddI, based upon patient and
physician reference
Naive to Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
Only subjects who meet the above criteria should contact the site for further information.
Contact:
Sandra Cassarella, R.N.
CSI / Paul J. Cimoch, M.D.
100 Pacifica, Suite 100
Irvine, CA 92618
Telephone: 949-753-0670
Fax: 949-753-0924
Email: sandcas@earthlink.net |
